LONDON--(BUSINESS WIRE)--
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) |
Millennium International Management LP |
Company dealt in |
Horizon Therapeutics plc |
Class of relevant security to which the dealings being disclosed relate (Note 2) |
IE00BQPVQZ61 |
Date of dealing |
25th August 2023 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
Long |
Short |
||||
|
Number |
|
(%) |
Number |
|
(%) |
(1) Relevant securities |
4,016,811
|
- |
||||
(2) Derivatives (other than options) |
- |
- |
||||
(3) Options and agreements to purchase/sell |
1,737,700
|
1,946,500
|
||||
Total |
5,754,511
|
1,946,500
|
||||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: |
Long |
Short |
||||
|
Number |
|
(%) |
Number |
|
(%) |
(1) Relevant securities |
|
|
||||
(2) Derivatives (other than options) |
|
|
||||
(3) Options and agreements to purchase/sell |
|
|
||||
Total |
|
|
||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD) (Note 5) |
Purchase |
96 |
106.56 |
Purchase |
152 |
106.50 |
Purchase |
31 |
106.45 |
Purchase |
31 |
106.51 |
Purchase |
13 |
106.58 |
Purchase |
50 |
106.54 |
Purchase |
3,479 |
112.00 |
Purchase |
29 |
106.63 |
Purchase |
4 |
106.43 |
Purchase |
148 |
112.47 |
Sale |
96 |
106.67 |
Purchase |
50 |
106.48 |
Purchase |
46 |
106.42 |
Purchase |
2,925 |
112.15 |
Purchase |
129 |
112.46 |
Purchase |
8,835 |
112.50 |
Purchase |
11,196 |
112.13 |
Purchase |
888 |
112.49 |
Purchase |
49 |
106.44 |
Purchase |
2,600 |
112.25 |
Purchase |
13 |
106.37 |
Sale |
12 |
106.55 |
Sale |
6 |
106.53 |
Sale |
50 |
106.54 |
Purchase |
6 |
106.36 |
Purchase |
74 |
106.67 |
Sale |
6 |
106.48 |
Purchase |
3 |
106.79 |
Purchase |
107 |
106.72 |
Purchase |
40 |
106.56 |
Sale |
1,552 |
106.56 |
Purchase |
5,000 |
106.55 |
Sale |
13,255 |
106.55 |
Purchase |
600 |
106.40 |
Purchase |
12,962 |
106.50 |
Sale |
3,999 |
106.50 |
Purchase |
420 |
106.49 |
Sale |
10,392 |
106.49 |
Sale |
8,276 |
106.46 |
Purchase |
748 |
106.45 |
Sale |
7,287 |
106.45 |
Purchase |
290 |
106.51 |
Sale |
17,125 |
106.51 |
Sale |
270 |
106.58 |
Sale |
1,375 |
106.53 |
Sale |
3,791 |
106.54 |
Purchase |
4,680 |
106.52 |
Sale |
6,649 |
106.52 |
Purchase |
300 |
106.47 |
Sale |
2,540 |
106.47 |
Sale |
475 |
106.36 |
Sale |
2,599 |
106.57 |
Purchase |
405 |
106.32 |
Sale |
365 |
106.63 |
Sale |
11,397 |
106.70 |
Sale |
20 |
106.59 |
Sale |
4 |
106.43 |
Sale |
2 |
106.67 |
Sale |
3,996 |
106.60 |
Sale |
6,315 |
106.48 |
Sale |
2,293 |
106.68 |
Sale |
4,214 |
107.10 |
Sale |
8,900 |
107.09 |
Sale |
100 |
106.66 |
Sale |
6,689 |
106.79 |
Sale |
1,600 |
106.78 |
Sale |
100 |
107.02 |
Purchase |
5,000 |
110.25 |
Sale |
606 |
106.35 |
Sale |
13,973 |
106.80 |
Sale |
2,700 |
106.90 |
Sale |
6,288 |
112.55 |
Sale |
415 |
106.72 |
Sale |
5,599 |
109.89 |
Sale |
2,430 |
106.65 |
Sale |
200 |
107.32 |
Sale |
1,264 |
109.50 |
Sale |
1,560 |
106.62 |
Sale |
2,348 |
106.61 |
Sale |
3,712 |
112.60 |
Sale |
100 |
107.27 |
Sale |
11,216 |
106.75 |
Sale |
5,676 |
106.82 |
Sale |
700 |
106.91 |
Sale |
100 |
109.75 |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD |
Nature of transaction (Note 6) |
Number of relevant securities (Note 7) |
Price per unit (USD) (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 7) |
Exercise price (USD) |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/received per unit (Note 5) |
Put Option |
Purchasing |
4,000 |
95.00 |
American |
10/20/2023 |
|
(ii) Exercising
Product name, e.g. call option |
Number of securities |
Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) |
Details |
Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None.
Is a Supplemental Form 8 attached? (Note 9) YES
Date of disclosure |
28th August 2023 |
Contact name |
Stephen Glasper |
Telephone number |
+44 203 398 2166 |
If a connected EFM, name of offeree/offeror with which connected |
|
If a connected EFM, state nature of connection (Note 10) |
|
Ap32
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES
1. KEY INFORMATION
Full name of person making
|
Millennium International Management LP |
Name of offeror/offeree in relation
|
Horizon Therapeutics plc |
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of
|
Product
|
Written or
|
Number of
|
Exercise
(USD) |
Type
|
Expiry
|
IE00BQPVQZ61 |
Put Option |
Purchased |
300 |
80.00 |
American |
1/17/2025 |
IE00BQPVQZ61 |
Put Option |
Purchased |
100,300 |
90.00 |
American |
1/19/2024 |
IE00BQPVQZ61 |
Put Option |
Written |
284,900 |
60.00 |
American |
12/15/2023 |
IE00BQPVQZ61 |
Put Option |
Written |
100,000 |
65.00 |
American |
7/21/2023 |
IE00BQPVQZ61 |
Put Option |
Purchased |
55,000 |
70.00 |
American |
1/19/2024 |
IE00BQPVQZ61 |
Put Option |
Written |
41,500 |
45.00 |
American |
1/19/2024 |
IE00BQPVQZ61 |
Put Option |
Purchased |
250,000 |
85.00 |
American |
1/19/2024 |
IE00BQPVQZ61 |
Call Option |
Purchased |
152,500 |
110.00 |
American |
17/11/2023 |
IE00BQPVQZ61 |
Call Option |
Purchased |
4,500 |
110.00 |
American |
10/20/2023 |
IE00BQPVQZ61 |
Call Option |
Purchased |
100,000 |
100.00 |
American |
12/15/2023 |
IE00BQPVQZ61 |
Call Option |
Written |
100,000 |
110.00 |
American |
12/15/2023 |
IE00BQPVQZ61 |
Call Option |
Written |
3,400 |
100.00 |
American |
10/20/2023 |
IE00BQPVQZ61 |
Call Option |
Purchased |
2,800 |
100.00 |
American |
17/11/2023 |
IE00BQPVQZ61 |
Put Option |
Written |
50,000 |
85.00 |
American |
15/09/2023 |
IE00BQPVQZ61 |
Put Option |
Purchased |
150,000 |
85.00 |
American |
17/11/2023 |
IE00BQPVQZ61 |
Put Option |
Purchased |
2,600 |
90.00 |
American |
17/11/2023 |
IE00BQPVQZ61 |
Put Option |
Purchased |
40,900 |
100.00 |
American |
17/11/2023 |
IE00BQPVQZ61 |
Put Option |
Purchased |
41,500 |
65.00 |
American |
1/19/2024 |
IE00BQPVQZ61 |
Put Option |
Written |
600 |
100.00 |
American |
10/20/2023 |
IE00BQPVQZ61 |
Put Option |
Purchased |
100,000 |
70.00 |
American |
17/11/2023 |
IE00BQPVQZ61 |
Call Option |
Purchased |
300 |
100.00 |
American |
15/09/2023 |
IE00BQPVQZ61 |
Put Option |
Purchased |
300 |
100.00 |
American |
15/09/2023 |
IE00BQPVQZ61 |
Put Option |
Written |
100,000 |
60.00 |
American |
1/19/2024 |
IE00BQPVQZ61 |
Call Option |
Purchased |
35,000 |
110.00 |
American |
15/09/2023 |
IE00BQPVQZ61 |
Call Option |
Purchased |
535,200 |
110.00 |
American |
1/19/2024 |
IE00BQPVQZ61 |
Call Option |
Written |
554,800 |
115.00 |
American |
1/19/2024 |
IE00BQPVQZ61 |
Put Option |
Purchased |
220,000 |
90.00 |
American |
15/09/2023 |
IE00BQPVQZ61 |
Call Option |
Purchased |
18,000 |
105.00 |
American |
15/09/2023 |
IE00BQPVQZ61 |
Call Option |
Written |
400 |
105.00 |
American |
17/11/2023 |
IE00BQPVQZ61 |
Put Option |
Written |
400 |
105.00 |
American |
17/11/2023 |
IE00BQPVQZ61 |
Put Option |
Written |
312,000 |
70.00 |
American |
10/20/2023 |
IE00BQPVQZ61 |
Put Option |
Purchased |
327,000 |
95.00 |
American |
10/20/2023 |
3. AGREEMENTS TO PURCHASE OR SELL
Full details should be given so that the nature of the interest or position can be fully understood: |
|
Ap33
4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)
Class of relevant security in relation to which subscription right exists: |
|
Details, including nature of the rights concerned and relevant percentages: |
|
It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.